First Week of ALNY February 2026 Options Trading

Options flow on Alnylam Pharmaceuticals (ALNY, current price $402.61) highlights a $400 put trading at a $25.20 bid (implying an effective purchase basis of $374.80 if assigned) with a 57% chance to expire worthless and a reported YieldBoost of 6.30% (36.50% annualized). On the call side, the $410 strike bids $28.10 for a covered-call that would yield 8.81% to $410 at the February 2026 expiry, with a 48% chance to expire worthless and a YieldBoost of 6.98% (40.44% annualized). Implied volatilities are ~46% (put) and 47% (call) versus a 12‑month realized volatility of 43%; the piece is an actionable options-idea briefing rather than company fundamental news.

Analysis

Market structure: Option sellers and income-focused equity holders are the immediate winners — selling the Feb‑2026 $400 puts (collect $25.20) or $410 covered calls ($28.10) generates a near‑term yield boost (6–7% absolute, ~36–40% annualized) while buyers of directional upside are capped. ALNY’s option market shows IV ~46–47% vs realized ~43%, signalling modestly elevated risk premia but not extreme mispricing; that supports premium collection strategies rather than aggressive directional longs. Flow-wise, sizeable put selling would increase implied bid for equity financing needs and could pin price near strike at expiration, while large call writing compresses upside volatility and may shift hedging flows into selling stock futures.

Risk assessment: Tail risks are classic biotech binary events — negative Phase III readout or FDA setbacks could trigger >30–50% moves within days, wiping out premiums; conversely an approval could re-rate shares >>50% over months. Short horizon (days–weeks): delta and IV moves dominate P&L; medium (3–9 months): premium decay and trial catalysts matter; long horizon (≥12 months): pipeline fundamentals, revenue guidance and royalty streams drive valuation. Hidden dependencies include counterparty concentration in options clearing, hedging gamma blowups if large positions need to be delta‑hedged, and macro rate moves compressing biotech multiples.

Trade implications: If willing to own ALNY, consider selling the Feb‑2026 $400 put as a way to acquire at $374.80 (limit sizing to 1–2% NAV) but cap downside with a protective bought put or a put spread (e.g., buy $340). If already long, sell the $410 Feb‑2026 covered call on 50–75% of the position to harvest the $28.10 premium, accepting the 8.8% capped return to Feb‑2026. For volatility arbitrage, favor selling vertical put spreads to collect yield while limiting tail (sell $400 / buy $340) and pair ALNY long with short XBI or IBB (0.5–0.75x) to reduce sector beta ahead of binary readouts.

Contrarian angles: The market is underpricing binary downside vs premium collected — 6–7% credit over ~1 year is small relative to potential single‑event drawdowns; the consensus income trade can be overstretched if an adverse readout occurs. Conversely, IV is only slightly rich to realized volatility, so buying calls ahead of positive catalysts at IV <45% becomes attractive — target Feb/Dec‑2026 calls if IV compresses <40% or after a dip >20%. Unintended consequence: heavy put selling can create a pin risk and force concentrated long assignments; size accordingly and hedge discrete event risk.

Key Decisions for Investors

• Sell-to-open ALNY Feb‑2026 $400 puts (collect ~$25.20) to obtain effective entry at $374.80 — size at 1–2% NAV max; simultaneously purchase downside protection (buy $340 puts) or structure as a $400/$340 put spread to limit worst-case assignment loss.
• If already long ALNY, sell-to-open Feb‑2026 $410 covered calls on 50–75% of holdings to capture $28.10 premium (locks ~8.8% total to Feb‑2026); roll or buy back if ALNY moves >+10% or if IV rises >15% pct points from current levels.
• Establish a relative‑value hedge: long ALNY vs short XBI (0.5–0.75x notional) for 3–9 months around upcoming trial/FDA catalysts to isolate idiosyncratic upside while cutting sector beta; trim/close if ALNY outperforms by >15%.
• Avoid naked long exposure >3% NAV ahead of major data; if you want upside exposure, buy long-dated calls (Feb/Dec‑2026) only when ALNY IV ≤40% or after a >20% drawdown — target 2–3% NAV in call premium.
• Monitor triggers: material trial readouts or FDA decisions within the next 90–180 days, IV moving above 50% (opportunity to sell premium), or a >20% price gap (re‑size/hedge positions within 48 hours).